Use of bisphosphonates in metastatic breast cancer: Single institution review at the Dr. H. Bliss Murphy Cancer Centre

Supportive Care in Cancer

Volumn 21, Issue 6, 2013, Pages 1557-1560

  Murphy, Laura ^a   McCarthy, Joy ^a   McCrate, Farah ^b   Laing, Kara ^a   Powell, Erin ^a   Seal, Melanie ^a   Edwards, Scott ^a  

^a MEMORIAL UNIVERSITY OF NEWFOUNDLAND   (Canada)

^b Cancer Care Program   (Canada)

Author keywords

Breast cancer; Metastasis; Pamidronate; Skeletal related events; Zolendronic acid

Indexed keywords

PAMIDRONIC ACID; ZOLEDRONIC ACID;

ADULT; AGED; BONE DENSITY; BONE DISEASE; BONE METASTASIS; BREAST METASTASIS; CANCER PATIENT; CANCER REGISTRY; DEMOGRAPHY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; FEMALE; HUMAN; HYPERCALCEMIA; MAJOR CLINICAL STUDY; MORBIDITY; OSTEOPENIA; OSTEOPOROSIS; POSTMENOPAUSE; PREMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; SKELETAL RELATED EVENT;

ADULT; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES; BONE NEOPLASMS; BREAST NEOPLASMS; CANCER CARE FACILITIES; DIPHOSPHONATES; FEMALE; FRACTURES, SPONTANEOUS; HUMANS; HYPERCALCEMIA; IMIDAZOLES; MIDDLE AGED; REGISTRIES; RETROSPECTIVE STUDIES; SPINAL CORD COMPRESSION;

EID: 84879159553     PISSN: 09414355     EISSN: 14337339     Source Type: Journal    
DOI: 10.1007/s00520-012-1694-2     Document Type: Review

References (21)

1. Du ZY, Zang J, Tang XD, Guo W (2010) Experts' agreement on therapy for bone metastases. Orthop Surg 2(4):241-253
2. Clemons MJ, Dranitsaris G, Ooi WS, Yogendran G, Sukovic T, Wong BY, Verma S, Pritchard KI, Trudeau M, Cole DE (2006) Phase II trial evaluating the palliative benefit of second-line zolendronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy. J Clin Oncol 24(30):4895-4900
3. Giordano SH, Fang S, Duan Z, Kuo YF, Hortobagyi GN, Goodwin JS (2008) Use of intravenous bisphosphonates in older women with breast cancer. Oncologist 13(5):494-502
4. Costa L, Major PP (2009) Effect of bisphosphonates on pain and quality of life in patients with bone metastases. Nat Clin Pract Oncol 6(3):163-174
5. Costa L, Badia X, Chow E, Lipton A, Wardley A (2008) Impact of skeletal complications on patients' quality of life, mobility, and functional independence. Support Care Cancer 16(8):879-889
6. American Society of Clinical Oncology (2011) American Society of Clinical Oncology executive summary of the clinical practice guideline update on the role of bone-modifying agents in metastatic breast cancer. J Clin Oncol 29(9):1221-1227
7. Gordon DH (2005) Efficacy and safety of intravenous bisphosphonates for patients with breast cancer metastatic to bone: a review of randomized, double-blind, phase III trials. Clin Breast Cancer 6(2):125-131
8. Wong MH, Stockler MR, Pavlakis N (2012) Bisphosphonates and other bone agents for breast cancer. Cochrane Database Syst Rev 2:CD003474
9. Lipton A, Cook R, Saad F, Major P, Garnero P, Terpos E, Brown JE, Coleman RE (2008) Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zolendronic acid. Cancer 113(1):193-201
10. Hortobagyi GN, Theriault RL, Lipton A, Porter L, Blayney D, Sinoff C, Wheeler H, Simeone JF, Seaman JJ, Knight RD, Heffernan M, Mellars K, Reitsma DJ (1998) Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 16(6):2038-2044
11. Lipton A (2005) Management of bone metastases in breast cancer. Curr Treat Options Oncol 6(2):161-171
12. Coleman RE (2002) Efficacy of zolendronic acid and pamidronate in breast cancer patients: a comparative analysis of randomized phase III trials. Am J Clin Oncol 25(6 Suppl 1):S25-S31
13. Nagykálnai T, Landherr L, Zatkóné GP, Gyuricska A (2002) Pamidronate in the treatment of bone metastases from breast cancer. Magy Onkol 46(3):225-233
14. Hultborn R, Gundersen S, Ryden S, Holmberg E, Carstensen J, Wallgren UB, Killany S, Andreassen L, Carlsson G, Fahl N, Hatschek T, Sommer HH, Hessman Y, Hornmark-Stenstam B, Johnsborg S, Klepp R, Laino R, Niklasson LG, Rudenstam CM, Sundbeck A, Söderberg M, Tejler G (1999) Efficacy of pamidronate in breast cancer with bone metastases: a randomized, double-blind placebo-controlled multicenter study. Anticancer Res 19(4C):3383-3392
15. Pavlakis N, Schmidt R, Stockler M (2005) Bisphosphonates for breast cancer. Cochrane Database Syst Rev 3:CD003474
16. Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, Watanabe GC, Ohashi Y, Takashima S (2005) Zolendronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial. J Clin Oncol 23(15):3314-3321
17. Liauw W, Segelov E, Lih A, Dunleavy R, Links M, Ward R (2006) Off-trial evaluation of bisphosphonates in patients with metastatic breast cancer. J Clin Oncol 24(30):4895-4900
18. Costa L, Lipton A, Coleman RE (2006) Role of bisphosphonates for the management of skeletal complications and bone pain from skeletal metastases. Support Cancer Ther 3(3):143-153
19. Major PP, Cook RJ, Chen BL, Zheng M (2005) Survival-adjusted multiple-event analysis for the evaluation of treatment effects of zolendronic acid in patients with bone metastases from solid tumors. Support Cancer Ther 2(4):234-240
20. Rosen LS, Gordon D, Kaminski M, Howell A, Belch A, Mackey J, Apffelstaedt J, Hussein MA, Coleman RE, Reitsma DJ, Chen BL, Seaman JJ (2003) Long-term efficacy and safety of zolendronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 98(8):1735-1744
21. Holen I, Coleman RE (2010) Bisphosphonates as treatment of bone metastases. Curr Pharm Des 16(11):1262-1271